Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The MYOCARDIAL ISCHEMIA market is significantly influenced by the high prevalence of cardiovascular diseases globally. As a leading cause of morbidity and mortality, myocardial ischemia, which involves insufficient blood flow to the heart muscle, creates a substantial market demand for diagnostic tools, treatments, and interventions.
Ongoing technological developments in pre medical diagnostics – ECG, stress testing, and advanced imaging modalities like CMR and CT angiography – are integral to the changing market dynamics. With the positive effect resulting from better accuracy and efficiency of diagnostics of myocardial ischemia when using these technologies, it has also grown acceptability among health professionals.
The myocardial ischemia risk linkage to modifiable risk factors such as hypertension, diabetes, and poor lifestyles is what informs the market. With growing awareness of how lifestyle influences cardiovascular health, preventive measures as well as early detection a d management of myocardial ischemia shape market dynamics.
A lot of R&D studies that are continually done about the drug development also boost the MYOCARDIAL ISCHEMIA market. Into various aspects of ischemic heart disease pharma companies invest in targeted therapies provided by antiplatelet agents, beta-blockers, and vasodilators. Modalities of treatment, intervention procedures and procedures of revascularization are other market determinants.
The aging world population is one of the big market determinants of MYOCARDIAL ISCHEMIA. As people become aged, the probability of getting cardiovascular diseases is also enhanced which has led to the growth in demand of diagnostic studies and treatment initiatives. Also, rising health care costs especially in developed world drive the market size.
In emerging economies, with a better quality of healthcare systems, considerable scope exists for the market expansion where multinational companies can penetrate. The regions see development, and improved health services provision, increase of myocardial ischemia cases can be observed for the need for treatment need increases. The entry of companies into such markets poses distinct challenges and evokes various opportunities.
The market is driven by the telemedicine and remote monitoring technology merged , thereby providing 24 hrs interaction on patients suffering from myocardial ischemia. Through remote monitoring, quick interventions are achieved thereby relieving the hospitals from the associated pressure. This trend accompanies the transforming landscape of myocardial ischemia care as companies adopting these advances.
Patient education and awareness programs for the early recognition of symptoms and modification of lifestyle. Companies engaging in initiatives aimed at educating the patients about the risks of myocardial ischemia and the need for seeking timely medical attention participate in the dynamics and positive evolutes of the market.
MYOCARDIAL ISCHEMIA market is strictly monitored by the legal bodies and following a strict obedience to the stringent approval processes is very essential for the market players. Being aware of the regulatory demands of diagnostic tests, drugs, and medical devices is very important to have a successful market entrance and further development. Reimbursement policies significantly impact the adoption of diagnostic tests and treatments for myocardial ischemia. Companies developing products that align with reimbursement policies are more likely to gain acceptance in the market. Understanding reimbursement dynamics is essential for market penetration and ensuring broader patient access to essential interventions.
Myocardial Ischemia Market Highlights:
Myocardial Ischemia Market Overview
The Myocardial Ischemia Market is expected to reach USD 1186.12 Million by 2030 at 5.70% CAGR during the forecast period 2022-2030 Myocardial ischemia is a medical condition characterized by the insufficient blood flow to the heart muscle via coronary arteries, commonly resulting in chest pain.
Factors such as the high prevalence of coronary heart disease, rising incidence of diabetes, and lifestyle changes provide suitable backgrounds for the development of market growth. However, the high cost of therapeutic surgeries and side effects related to medications are projected to restrain the market growth during the forecast period.
Market Dynamics
Myocardial ischemia is a common occurrence and occurs with increased frequency in patients with diabetes due to cardiac autonomic dysfunction. According to a study published in the Endocrinology, Diabetes & Metabolism Case Reports journal in 2013, ~22% of the patients diagnosed with type 2 diabetes were estimated to suffer from Silent Myocardial Ischemia (SMI). Moreover, it is reported that the prevalence of diabetes has increased. This is illustrative by the fact sheet of the World Health Organization (WHO) published in 2017. According to it, the global prevalence of diabetes among individuals ages 18 years or more was about 8.5% in 2014. Thus, it is interpreted that the rising prevalence of diabetes provides a necessary driving force for the myocardial ischemia market to expand.
Myocardial Ischemia Market Size, by End User, 2017 (USD Million)  
 Source: MRFR Analysis
Segmentation
The myocardial ischemia market has been segmented into type, treatment & diagnosis, and end user. By type, the market has been bifurcated into symptomatic and asymptomatic. Based on treatment & diagnosis, the market has been divided into diagnosis and treatment. Diagnosis segment has been further segregated into imaging and stress test. The treatment has been further divided into medications and surgery. By end-user, the market has been classified as hospitals & clinics, diagnostic centers, ambulatory surgery centers, and others. The hospitals and clinics accounted for a market value of USD 18,744.2 million in 2023.
Key Players
The prominent players in the myocardial ischemia market are Taxus Cardium (US), ViroMed Co. Ltd. (Republic of Korea ), Edward Lifesciences (US), Daiichi Sankyo Company Limited (Japan), Boston Scientific Corporation (US), Merck KGaA (Germany), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), and AstraZeneca (UK).
Some of the key strategies followed by the players operating in the myocardial ischemia market were innovation, product development, acquisition, and expansion.
Asia-Pacific Myocardial Ischemia Market Share, by Country, 2017 (%) 
Source: MRFR Analysis
Regional Analysis
The myocardial ischemia market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is estimated to dominate the brain ischemia ischemiamarket during the forecast period. Americas accounts for the largest regional market owing to the rising prevalence of diabetes, obesity, physical inactivity, and excessive alcohol use among the population. The European market for myocardial ischemia is expected to be the second-largest during the forecast period. The high growth rate is due to the high incidence rate of cardiovascular diseases in Europe. According to the European Cardiovascular Disease Statistics 2017, 45% of deaths in Europe is due to cardiovascular diseases (CVD).
Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth. Asia-Pacific is estimated to be the fastest-growing market due to the rising prevalence of diabetes. According to the Asian Diabetes Prevention Initiative, 60% of the world’s diabetic patient live in Asia. Such high incidences of diabetes that lead to silent myocardial ischemia are likely to fuel the market growth.
Moreover, in the Asia-Pacific region, China accounted for a market share of 23.5% in 2017. However, the Middle East and Africa are expected to observe slow growth due to less exposure to healthcare services and stringent government rules and regulations.
Key Updates
- In July 2016, Angionetics Inc., a subsidiary of Taxus Cardium, entered into an agreement with Huapont Life Sciences covering a USD 3,000,000 investment, to support the Generx Phase 3 clinical and commercialization development program.
- In February 2018, Edwards Lifesciences Corporation received the CE Mark for its self-expanding CENTERA valve, thus enhancing its transcatheter heart valve therapy segment.
- In August 2017, Boehringer Ingelheim Pharmaceuticals, Inc. received FDA approval for CyltezoTM (adalimumab-adbm).
Market Segmentation
Myocardial Ischemia Market, by Type
- Symptomatic
- Asymptomatic
Myocardial Ischemia Market, by Treatment & Diagnosis
- Diagnosis
- Treatment
Myocardial Ischemia Market, by End User
- Hospitals & Clinics
- Diagnostic Centres
- Ambulatory Surgery Centres
Myocardial Ischemia Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Republic of Korea
- Rest of Asia-Pacific
- Middle East & Africa
- United Arab Emirates
- Saudi Arabia
- Oman
- Kuwait
- Qatar
- Rest of The Middle East & Africa
Available Additional Customizations
- Regulatory scenario
Intended Audience
- Medical device manufacturers and distributors
- Government research organizations
- Hospitals and clinics
- Regulatory agencies
- Pharmaceutical companies
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
